InvestorsHub Logo
Followers 547
Posts 8257
Boards Moderated 3
Alias Born 10/23/2016

Re: tchalla post# 23008

Saturday, 09/19/2020 1:22:22 PM

Saturday, September 19, 2020 1:22:22 PM

Post# of 199220
ENZC already passed Phase III trials. 80% kill rate of HIV.

...this is a great thing for the world.....what do you not like about it, lol?


Most biotechs and new drugs do not make it past preclinical stages and Phase I. Then those that do...most dont make it past Phase II.. But ENZC’s ImmunH did. Under strict European Guidelines ENZC w B-G Europe ImmunH incredibly, already passed Phase I.....and Phase II....:

https://www.businesswire.com/news/home/20140828005129/en/Immunotech-Laboratories-Announces-Successful-Completion-Phase-Phase

and even yes, Phase III clinical trials:

https://www.accesswire.com/453497/Immunotech-Laboratories-Inc-Announces-Successful-Completion-of-Phase-III-Testing-of-the-Patented-Immune-Therapeutic-Vaccine-1

Why is this a big deal? Because of the time and money spent over the years trying to pass a new drug through Trials is a big risk, as most dont make it. Estimated 1 in 5,000 new drugs make it from Preclinical to Phase IV:

“Only 5 in 5,000 drugs that enter preclinical testing progress to human testing. One of these 5 drugs that are tested in people is approved. The chance for a new drug to actually make it to market is thus only 1 in 5,000. Not very good odds.”

https://www.medicinenet.com/script/main/art.asp?articlekey=9877

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENZC News